from Robert Wood Johnson Medical School at Rutgers University. Li has authored over 40 publications and is the primary inventor for seven issued patents. She served as the President of the Chinese Biopharmaceutical Association and co-founded the Alliance of ALL-CABPA in 2008.ĭr. In 2014, she received the Rising Star Award from the Healthcare Businesswomen’s Association. She played key roles in the development of 3 approved products and contributed to over 30 clinical development programs. She was a R&D Director and Fellow at MedImmune/AstraZeneca and Senior Director of Purification Sciences at HGS (now GSK).
Yuling Li is a seasoned executive with proven experience in biopharmaceutical development from clinical to commercialization. Zhao is co-founder of Tmunity Therapeutics.ĭr. Zhao has over 50 TCR-T and CART related publications and filed over 90 patents. Zhao has more than 20 years’ experiences in T cell engineering and his seminal work directly led to multiple clinical trials of treating cancer patients with T cells modified with TCR, CARs and CRISPR genome editing. The research work at the University of Pennsylvania let to multiple clinical trials using CART or TCR T to treat cancer patients. He joined the faculty of the Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine in 2009 as an Adjunct Associate Professor and the Director of T Cell Engineering Lab. Steven Rosenberg’s group as a senior research fellow at the Surgery Branch of the National Cancer Institute, where his research work directly led to clinical trials of treating cancer patients with T cells against NY-ESO-1, Her2/Neu, CD19 or VEGFR. For the next two years he was a research associate at Duke University Medical Center, where he worked on RNA transfected dendritic cell vaccines against cancers. From 1996 – 2000, he was a visiting scientist at The Weizmann Institute of Science in Rehovot, Israel, where he studied tolerance induction through genetically engineered T cells for allogeneic bone marrow transplantation. He received an MD and PhD in Immunology from the Third Military Medical University in Chongqing. Yangbing Zhao is the President and CSO of UTC Therapeutics Inc. He has written for Scientific American and Wired and has been interviewed by the NY Times, Wall Street Journal, Washington Post, NPR, Time Magazine, National Geographic, Bloomberg, Forbes, BBC, and other international media outlets.ĭr. Coulter Award for Healthcare Innovation, the National Marrow Donor Program/Be The Match ONE Forum 2020 Dennis Confer Innovate Award, serves as President of the International Society for Cell and Gene Therapy, and serves on the Board of Directors of the Alliance for Regenerative Medicine. Levine is a recipient of the William Osler Patient Oriented Research Award, the Wallace H. He is a Co-Founder of Tmunity Therapeutics, a spinout of the University of Pennsylvania. Levine is co-inventor on 28 issued US patents and co-author of >180 manuscripts and book chapters with a Google Scholar citation h-index of 89. He is co-inventor of the first FDA approved gene therapy (Kymriah), chimeric antigen receptor T cells for leukemia and lymphoma, licensed to Novartis. Levine has overseen the production, testing and release of 3,000 cellular products administered to >1,300 patients in clinical trials since 1996. First-in-human adoptive immunotherapy trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. in Immunology and Infectious Diseases from Johns Hopkins. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania.